Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)

Sohan Lal Solanki, Sudipta Mukherjee, Vandana Agarwal, Raghu S Thota, Kalpana Balakrishnan, Shagun Bhatia Shah, Neha Desai, Rakesh Garg, Reshma P Ambulkar, Nitin Madhukar Bhorkar, Viplab Patro, Snita Sinukumar, Meenakshi V Venketeswaran, Malini P Joshi, Rajesh Holalu Chikkalingegowda, Vijaya Gottumukkala, Pascal Owusu-Agyemang, Avanish P Saklani, Sanket Sharad Mehta, Ramakrishnan Ayloor Seshadri, John C Bell, Sushma Bhatnagar, Jigeeshu V Divatia, Sohan Lal Solanki, Sudipta Mukherjee, Vandana Agarwal, Raghu S Thota, Kalpana Balakrishnan, Shagun Bhatia Shah, Neha Desai, Rakesh Garg, Reshma P Ambulkar, Nitin Madhukar Bhorkar, Viplab Patro, Snita Sinukumar, Meenakshi V Venketeswaran, Malini P Joshi, Rajesh Holalu Chikkalingegowda, Vijaya Gottumukkala, Pascal Owusu-Agyemang, Avanish P Saklani, Sanket Sharad Mehta, Ramakrishnan Ayloor Seshadri, John C Bell, Sushma Bhatnagar, Jigeeshu V Divatia

Abstract

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for primary peritoneal malignancies or peritoneal spread of malignant neoplasm is being done at many centres worldwide. Perioperative management is challenging with varied haemodynamic and temperature instabilities, and the literature is scarce in many aspects of its perioperative management. There is a need to have coalition of the existing evidence and experts' consensus opinion for better perioperative management. The purpose of this consensus practice guideline is to provide consensus for best practice pattern based on the best available evidence by the expert committee of the Society of Onco-Anaesthesia and Perioperative Care comprising perioperative physicians for better perioperative management of patients of CRS-HIPEC.

Keywords: Consensus; cytoreduction surgical procedures; hyperthermia; induced; peritoneal neoplasms; peritoneum.

Conflict of interest statement

There are no conflicts of interest.

Copyright: © 2019 Indian Journal of Anaesthesia.

Figures

Figure 1
Figure 1
Sugarbaker's Peritoneal Carcinomatosis Index scoring

References

    1. Sugarbaker PH. Surgical management of peritoneal carcinosis: Diagnosis, prevention and treatment. Langenbecks Arch Chir. 1988;373:189–96.
    1. Dubé P, Sideris L, Law C, Mack L, Haase E, Giacomantonio C, et al. Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms. Curr Oncol. 2015;22:e100–12.
    1. Kusamura S, Dominique E, Baratti D, Younan R, Deraco M. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2008;98:247–52.
    1. Helderman RFCPA, Löke DR, Kok HP, Oei AL, Tanis PJ, Franken NAPK, et al. Variation in clinical application of hyperthermic intraperitoneal chemotherapy: A review. Cancers (Basel) 2019;11:78.
    1. Holey EA, Feeley JL, Dixon J, Whittaker VJ. An exploration of the use of simple statistics to measure consensus and stability in Delphi studies. BMC Med Res Methodol. 2007;7:52.
    1. Cederholm T, Barazzoni R, Austin P, Ballmer P, Boilo G, Bischoff SG, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 2017;36:49–64.
    1. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009;249:900–7.
    1. Dayal S, Taflampas P, Riss S, Chandrakumaran K, Cecil TD, Mohamed F, et al. Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved. Dis Colon Rectum. 2013;56:1366–72.
    1. Cotte E, Passot G, Gilly F-N, Glehen O. Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol. 2010;2:31–5.
    1. Coccolini F, Catena F, Glehen O, Yonemura Y, Sugarbaker PH, Piso P, et al. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2015;41:911–9.
    1. Shinde RS, Acharya R, Kumar NA, Solanki S, Desouza A, Saklani A. Pelvic Exenteration with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) for rectal cancer – Case series with review of literature. Indian J Surg Oncol. 2019;10(Suppl 1):80–3.
    1. Rothfield KP, Crowley K. Anesthesia considerations during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Surg Oncol Clin N Am. 2012;21:533–41.
    1. Raspé C, Flöther L, Schneider R, Bucher M, Piso P. Best practice for perioperative management of patients with cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2017;43:1013–27.
    1. Burden S, Todd C, Hill J, Lal S. Pre-operative nutrition support in patients undergoing gastrointestinal surgery. Cochrane Database Syst Rev. 2012;(Issue 11) Art. No.: CD008879.
    1. Reece L, Dragicevich H, Lewis C, Rothwell C, Fisher OM, Carey S, et al. Preoperative nutrition status and postoperative outcomes in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2019;26:2622–30.
    1. Vashi PG, Gupta D, Lammersfeld CA, Braun DP, Popiel B, Misra S, et al. The relationship between baseline nutritional status with subsequent parenteral nutrition and clinical outcomes in cancer patients undergoing hyperthermic intraperitoneal chemotherapy. Nutr J. 2013;12:118.
    1. Weimann A, Braga M, Carli F, Higashiguchi T, Hubner M, Klek S, et al. ESPEN guideline: Clinical nutrition in surgery. Clin Nutr. 2017;36:623–50.
    1. McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) JPEN J Parenter Enteral Nutr. 2016;40:159–211.
    1. Li K, Xu Y, Hu Y, Liu Y, Chen X, Zhou Y. Effect of enteral immunonutrition on immune, inflammatory markers and nutritional status in gastric cancer patients undergoing gastrectomy: A randomized double-blinded controlled trial. J Invest Surg. 2019;19:1–10.
    1. Challine A, Rives-Langes C, Danoussou D, Katsahian S, Ait Boudaoud A, Gaujoux S, et al. Impact of oral immunonutrition on postoperative morbidity in digestive oncologic surgery: A nation-wide cohort study. Ann Surg. 2019 doi: 10.1097/SLA.0000000000003282.
    1. Pearse RM, Holt PJ, Grocott MP. Managing perioperative risk in patients undergoing elective non-cardiac surgery. Br Med J. 2011;343:734–9.
    1. Saxena A, Yan TD, Chua TC, Fransi S, Almohaimeed K, Ahmed S, et al. Risk factors for massive blood transfusion in cytoreductive surgery: A multivariate analysis of 243 procedures. Ann Surg Oncol. 2009;16:2195–203.
    1. Musallam KM, Tamim HM, Richards T, Spahn DR, Rosendaal FR, Habbal A, et al. Preoperative anemia and postoperative outcomes in non-cardiac surgery: A retrospective cohort study. Lancet. 2011;378:1396–407.
    1. Sheshadri DB, Chakravarthy MR. Anaesthetic considerations in the perioperative management of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Indian J Surg Oncol. 2016;7:236–43.
    1. Webb CAJ, Weyker PD, Moitra VK, Raker RK. An overview of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for the anesthesiologist. Anesth Analg. 2013;116:924–31.
    1. Valle SJ, Alzahrani NA, Liauw W, Sugarbaker PH, Bhatt A, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) methodology, drugs and bidirectional chemotherapy. Indian J Surg Oncol. 2016;7:152–9.
    1. Mehta AM, Van den Hoven JM, Rosing H, Hillebrand MJ, Nuijen B, Huitema AD, et al. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharm. 2015;479:23–7.
    1. Byrne K, Levins KJ, Buggy DJ. Can anesthetic-analgesic technique during primary cancer surgery affect recurrence or metastasis? Can J Anesth. 2016;63:184–192.
    1. Connolly C, Buggy DJ. Opioids and tumour metastasis: Does the choice of the anesthetic-analgesic technique influence outcome after cancer surgery? Curr Opin Anaesthesiol. 2016;29:468–74.
    1. Yap A, Lopez-Olivo MA, Dubowitz J, Hiller J, Riedel B. Global Onco-Anesthesia Research Collaboration Group. Anesthetic technique and cancer outcomes: A meta-analysis of total intravenous versus volatile anesthesia. Can J Anaesth. 2019;66:546–61.
    1. Wigmore TJ, Mohammed K, Jhanji S. Long-term survival for patients undergoing volatile versus IV anesthesia for cancer surgery: A retrospective analysis. Anesthesiology. 2016;124:69–79.
    1. Wu ZF, Lee MS, Wong CS, Lu CH, Huang YS, Lin KT, et al. Propofol-based total intravenous anesthesia is associated with better survival than desflurane anesthesia in colon cancer surgery. Anesthesiology. 2018;129:932–41.
    1. Zhou X, Zhang P, Luo W, Zhang L, Hu R, Sun Y, et al. Ketamine induces apoptosis in lung adenocarcinoma cells by regulating the expression of CD69. Cancer Med. 2018;7:788–95.
    1. Cata JP, Nguyen LT, Ifeanyi-Pillette IC, Van Meter A, Dangler LA, Feng L, et al. An assessment of the survival impact of multimodal anesthesia/analgesia technique in adults undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: A propensity score matched analysis. Int J Hyperthermia. 2019;36:369–75.
    1. Marik PE, Cavallazzi R. Does the central venous pressure predict fluid responsiveness? An updated meta-analysis and a plea for some common sense. Crit Care Med. 2013;41:1774–81.
    1. Polderman KH, Varon J, Marik PE. Fluid management decisions should not be guided by fixed central venous pressure targets. Am J Emerg Med. 2015;33:1311.
    1. Solanki SL, Bajaj JS, Rahman F, Saklani AP. Perioperative management of cytoreductive surgery and hyperthermic intraoperative thoraco-abdominal chemotherapy (HITAC) for pseudomyxoma peritonei. Indian J Anaesth. 2019;63:134–7.
    1. Balakrishnan KP, Survesan S. Anaesthetic management and perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: A retrospective analysis. Indian J Anaesth. 2018;62:188–96.
    1. Mavroudis C, Alevizos L, Stamou KM, Vogiatzaki T, Eleftheriadis S, Korakianitis O, et al. Hemodynamic monitoring during heated intraoperative intraperitoneal chemotherapy using the FloTrac/Vigileo system. Int Surg. 2015;100:1033–9.
    1. Colantonio L, Claroni C, Fabrizi L, Marcelli ME, Sofra M, Giannarelli D, et al. A randomized trial of goal directed vs. standard fluid therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Gastrointest Surg. 2015;19:722–9.
    1. Escobar B, Medina-Piedrahita P, Gómez-Henao P, Higuera-Palacio A, García-Mora M, Ruiz-Villa JO, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: Main concepts for anaesthetists. Rev Colomb Anestesiol. 2018;46:134–42.
    1. Hakeam HA, Breakiet M, Azzam A, Nadeem A, Amin T. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail. 2014;36:1486–91.
    1. Hayati F, Hossainzadeh M, Shayanpour S, Abedi-Gheshlaghi Z, Beladi Mousavi SS. Prevention of cisplatin nephrotoxicity. J Nephropharmacol. 2015;5:57–60.
    1. Cata JP, Zavala AM, Van Meter A, Williams UU, Soliz J, Hernandez M, Owusu-Agyemang P. Identification of risk factors associated with postoperativeacute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: A retrospective study. Int J Hyperthermia. 2018;34:538–44.
    1. Angeles MA, Quenet F, Vieille P, Gladieff L, Ruiz J, Picard M, et al. Predictive risk factors of acute kidney injury after cytoreductive surgery and cisplatin-based hyperthermic intra-peritoneal chemotherapy for ovarian peritoneal carcinomatosis. Int J Gynecol Cancer. 2019;29:382–91.
    1. Schumann R, Wilson G, Hariskov S, Buck D, Goodman M, Balonov K, et al. Impact of intraperative anaesthetic and fluid management on 30 day postoperative outcomes in a newly established surgical peritoneal surface malignancy program. J Anesth Clin Res. 2012;3:1–4.
    1. Eng OS, Dumitra S, O'Leary M, Raoof M, Wakabayashi M, Dellinger TH, et al. Association of fluid administration with morbidity in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. JAMA Surg. 2017;152:1156–60.
    1. Bell JC, Rylah BG, Chambers RW, Peet H, Mohamed F, Moran BJ. Perioperative management of patients undergoing cytoreductive surgery combined with heated intraperitoneal chemotherapy for peritoneal surface malignancy: A multi-institutional experience. Ann Surg Oncol. 2012;19:4244–51.
    1. Schmidt C, Piso P, Wiesenack C, Bucher M. Anesthetic management in patients undergoing hyperthermic chemotherapy. Curr Opin Anaesthesiol. 2012;25:348–55.
    1. Thong SY, Chia CS, Ng O, Tan G, Ong ET, Soo KC, et al. A review of 111 anaesthetic patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Singapore Med J. 2017;58:488–96.
    1. Gupta N, Kumar V, Garg R, Bharti SJ, Mishta S, Bhatnagar S. Anaesthetic implications in hyperthermic intraperitoneal chemotherapy. J Aaesthesiol Clin Pharmacol. 2019;35:3–11.
    1. Stens J, Hering JP, van der Hoeven CWP, Boom A, Traast HS, Garmers LE, et al. The added value of cardiac index and pulse pressure variation monitoring to mean arterial pressure-guided volume therapy in moderate-risk abdominal surgery (COGUIDE): A pragmatic multicentre randomised controlled trial. Anaesthesia. 2017;72:1078–87.
    1. Schmid S, Kapfer B, Heim M, Bogdanski R, Anetsberger A, Blobner M, Jungwirth B. Algorithm-guided goaldirected haemodynamic therapy does not improve renal function after major abdominal surgery compared to good standard clinical care: A prospective randomised trial. Crit Care. 2016;20:50.
    1. Myburgh JA, Finfer S, Billot L. CHEST Investigators: Hydroxyethyl starch or saline in intensive care. N Engl J Med. 2013;368:775.
    1. Müller RB, Haase N, Lange T, Wetterslev J, Perner A. Acute kidney injury with hydroxyethyl starch 130/0.42 in severe sepsis. Acta Anaesthesiol Scand. 2015;59:329–36.
    1. Kammerer T, Brettner F, Hilferink S, Hulde N, Klug F, Pagel J, et al. No differences in renal function between balanced 6% hydroxyethyl starch (130/0.4) and 5% albumin for volume replacement therapy in patients undergoing cystectomy: A randomized controlled trial. Anesthesiology. 2018;128:67–78.
    1. Joosten A, Delaporte A, Ickx B, Touihri K, Stany I, Barvais L, et al. Crystalloid versus colloid for intraoperative goal-directed fluid therapy using a closed-loop system: A randomized, double-blinded, controlled trial in major abdominal surgery. Anesthesiology. 2018;128:55–66.
    1. Kajdi ME, Beck-Schimmer B, Held U, Kofmehl R, Lehmann K, Ganter MT. Anaesthesia in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: Retrospective analysis of a single centre three-year experience. World J Surg Oncol. 2014;12:136.
    1. Rasmussen KC, Secher NH, Pedersen T. Effect of perioperative crystalloid or colloid fluid therapy on hemorrhage, coagulation competence, and outcome: A systematic review and stratified meta-analysis. Medicine (Baltimore) 2016;95:e4498.
    1. Raghunathan K, Shaw A, Nathanson B, Stürmer T, Brookhart A, Stefan MS, et al. Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis*. Crit Care Med. 2014;42:1585–91.
    1. McCluskey SA, Karkouti K, Wijeysundera D, Minkovich L, Tait G, Beattie WS. Hyperchloremia after noncardiac surgery is independently associated with increased morbidity and mortality: A propensity-matched cohort study. Anesth Analg. 2013;117:412–21.
    1. Brandstrup B, Tønnesen H, Beier-Holgersen R, Hjortsø E, Ørding H, Lindorff-Larsen K, et al. Danish Study Group on Perioperative Fluid Therapy. Effects of intravenous fluid restriction on postoperative complications: Comparison of two perioperative fluid regimens: A randomized assessor-blinded multicenter trial. Ann Surg. 2003;238:641–8.
    1. Nisanevich V, Felsenstein I, Almogy G, Weissman C, Einav S, Matot I. Effect of intraoperative fluid management on outcome after intraabdominal surgery. Anesthesiology. 2005;103:25–32.
    1. Hendrix RJ, Damle A, Williams C, Harris A, Spanakis S, Lambert DH, et al. Restrictive intraoperative fluid therapy is associated with decreased morbidity and length of stay following hyperthermic intraperitoneal chemoperfusion. Ann Surg Oncol. 2019;26:490–6.
    1. Joshi GP. Intraoperative fluid restriction improves outcome after major elective gastrointestinal surgery. Anesth Analg. 2005;101:601–5.
    1. Vorgias G, Iavazzo C, Mavromatis J, Leontara J, Katsoulis M, Kalinoglou N, et al. Determination of the necessary total protein substitution requirements in patients with advanced stage ovarian cancer and ascites, undergoing debulking surgery. Correlation with plasma proteins. Ann Surg Oncol. 2007;14:1919–23.
    1. Miao N, Pingpank JF, Alexander HR, Royal R, Steinberg SM, Quezado MM, et al. Cytoreductive surgery and continuous hyperthermic peritoneal perfusion in patients with mesothelioma and peritoneal carcinomatosis: Hemodynamic, metabolic, and anesthetic considerations. Ann Surg Oncol. 2009;16:334–44.
    1. Garg R. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Fluid and temperature remain the culprit! Indian J Anaesth. 2018;62:162–5.
    1. Laplace N, Kepenekian V, Mercier F, Friggeri A, Bakrin N, Passot G, et al. Renal protection with sodium thiosulfate during hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin. Pleura Peritoneum. 2018;1(Special Suppl):sA6–463.
    1. Falcón Araña L, Fuentes-García D, Roca Calvo MJ, Hernández-Palazón J, Gil Martínez J, Cascales Campos PA, et al. Alterations in hemostasis during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis. Cir Esp. 2015;93:496–501.
    1. Esquivel J, Angulo F, Bland RK, Stephens AD, Sugarbaker PH. Hemodynamic and cardiac function parameters during heated intraoperative intraperitoneal chemotherapy using the open 'coliseum technique'. Ann Surg Oncol. 2000;7:296–300.
    1. Reynolds L, Beckmann J, Kurz A. Perioperative complications of hypothermia. Best Pract Res Clin Anaesthesiol. 2008;22:645–57.
    1. Said ET, Sztain JF, Abramson WB, Meineke MN, Furnish TJ, Schmidt UH, et al. A dedicated acute pain service is associated with reduced postoperative opioid requirements in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Anesth Analg. 2018;127:1044.
    1. Piso P, Glockzin G, Von Breitenbuch P, Popp FC, Dahlke MH, Schlitt HJ, et al. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. J Surg Oncol. 2009;15(100):317–20.
    1. McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitonealhyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2003;10:155–62.
    1. Schmidt C, Moritz S, Rath S, Grossmann E, Wiesenack C, Piso P, et al. Perioperative management of patients with cytoreductive surgery for peritoneal carcinomatosis. J Surg Oncol. 2009;100:297–301.
    1. Cooksley TJ, Haji-Michael P. Post-operative critical care management of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC) World J Surg Oncol. 2011;9:169.
    1. Teoh DA, Hutton MJ, Else S, Walker A, Lee A, Mack LA. Epidural analgesia? A prospective analysis of perioperative coagulation in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Am J Sur. 2019;217:887–92.
    1. Owusu-Agyemang P, Soliz J, Hayes-Jordan A, Harun N, Gottumukkala V. Safety of epidural analgesia in the perioperative care of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2014;21:1487–93.
    1. Kochhar P, Sagadei S, Beards S, Tansey D, Maguire SL. Postoperative outcomes in patients with Pseudomyxoma Peritonei undergoing cytoreductive surgery and hyperthermic intraoperative chemotherapy – A UK perspective. Eur J Anaesthesiol. 2007;24:160.
    1. Kapoor S, Bassily-Marcus A, Alba Yunen R, Tabrizian P, Semoin S, Blankush J, et al. Critical care management and intensive care unit outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. World J Crit Care Med. 2017;6:116–23.
    1. Mogal HD, Levine EA, Fino NF, Obiora C, Shen P, Stewart JH, et al. Routine admission to intensive care unit after cytoreductive surgery and heated intraperitoneal chemotherapy: Not always a requirement. Ann Surg Oncol. 2016;23:1486–95.
    1. Piccioni F, Casiraghi C, Fumagalli L, Kusamura S, Baratti D, Deraco M, et al. Epidural analgesia for cytoreductive surgery with peritonectomy and heated intraperitoneal chemotherapy. Int J Surg. 2015;16(Pt A):99–106.
    1. Baratti D, Kusamura S, Laterza B, Balestra MR, Deraco M. Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Gastrointest Oncol. 2010;2:36–43.
    1. Padmakumar AV. Intensive care management of patient after cytoreductive surgery and HIPEC – A concise review. Indian J Surg Oncol. 2016;7:244–8.
    1. de Witte P, de Witt CA, van de Minkelis JL, Boerma D, Solinger HF, Hack CE, et al. Inflammatory response and optimalisation of perioperative fluid administration during hyperthermic intraoperative intraperitoneal chemotherapy surgery. J Gastrointest Oncol. 2019;10:244–53.
    1. Shannon NB, Tan GHC, Chia CS, Soo KC, Teo MC. Does having a gastrectomy delay time to feeding and prolong hospital stay in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Int J Hyperthermia. 2018;34:518–23.
    1. Swain DR, Yates AL, Mohamed F, Dayal SP, Tzivanakis A, Cecil TD, et al. Do patients undergoing cytoreductive surgery and HIPEC for peritoneal malignancy need parenteral nutrition? Pleura Peritoneum. 2018;3:20180123.
    1. Saxena A, Yan TD, Chua TC, Morris DL. Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2010;17:1291–301.
    1. Simkens GA, van Oudheusden TR, Luyer MD, Nienhuijs SW, Nieuwenhuijzen GA, Rutten HJ, et al. Serious postoperative complications affect early recurrence after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2015;22:2656–62.
    1. Mizumoto A, Canbay E, Hirano M, Takao N, Matsuda T, Ichinose M, et al. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan. Gastroenterol Res Pract. 2012;2012:836425.
    1. Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. French Surgical Association. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: A multi-institutional study of 1,290 patients. Cancer. 2010;116:5608–18.
    1. Chua TC, Saxena A, Schellekens JF, Liauw W, Yan TD, Fransi S, et al. Morbidity and mortality outcomes of cytoreductive surgery and perioperativeintraperitoneal chemotherapy at a single tertiary institution: Towards a new perspective of this treatment. Ann Surg. 2010;251:101–6.
    1. Zmora O, Hayes-Jordan A, Nissan A, Kventsel I, Newmann Y, Itskovsky K, et al. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for disseminated intra-abdominal malignancies in children – A single-institution experience. J Pediatr Surg. 2018;53:1381–6.
    1. Owusu-Agyemang P, Arunkumar R, Green H, Hurst D, Landoski K, Hayes-Jordan A. Anesthetic management and renal function in pediatric patients undergoing cytoreductive surgery with continuous hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin. Ann Surg Oncol. 2012;19:2652–6.
    1. Owusu-Agyemang P, Williams UU, Van Meter A, Zavala MM, Rebello E, Feng L, et al. Investigating the association between perioperative blood transfusions and outcomes in children undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Vox Sang. 2017;112:40–6.
    1. Stiles ZE, Murphy AJ, Anghelescu DL, Brown CL, Davidoff AM, Dickson PV, et al. Desmoplastic small round cell tumor: Long-term complications after cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2019 doi: 10.1245/s10434-019-07339-2.
    1. Chua C, Yan T, Yap Z, Horton M, Fermanis GG, Morris DL. Thoracic cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy for pseudomyxoma peritonei. J Surg Oncol. 2009;99:292–5.
    1. Tilleman TR, Richards WG, Zellos L, Johnson BE, Jaklitsch MT, Mueller J, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: A phase II prospective study. J Thorac Cardiovasc Surg. 2009;138:405–11.
    1. Ried M, Potzger T, Braune N, Neu R, Zausig Y, Schalke B, et al. Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: Perioperative management and clinical experience. Eur J Cardiothorac Surg. 2013;43:801–7.
    1. Zhou H, Wu W, Tang X, Zhou J, Shen Y. Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion: A systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e5532.
    1. Solass W, Herbette A, Schwarz T, Hetzel A, Sun JS, Dutreix M, et al. Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination capnoperitoneum: Proof of concept. Surg Endosc. 2012;26:847–52.
    1. Solass W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): Occupational health and safety aspects. Ann Surg Oncol. 2013;20:3504–11.
    1. Delhorme JB, Klipfel A, D'Antonio F, Greget MC, Diemunsch P, Rohr S, et al. Occupational safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in an operating room without laminar airflow. J Visc Surg. 2019:pii: S1878.
    1. Graversen M, Detlefsen S, Bjerregaard JK, Fristrup CW, Pfeiffer P, Mortensen MB. Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther Adv Med Oncol. 2018;10:1758835918777036.
    1. Graversen M, Detlefsen S, Pfeiffer P, Lundell L, Mortensen MB. Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): Report of two cases and literature survey. Clin Exp Metastasis. 2018;35:103–8.
    1. Solanki SL, Kumar PP, DeSouza A Saklani AP. Perioperative concerns and management of pressurised intraperitoneal aerosolised chemotherapy: Report of two cases. Indian J Anaesth. 2018;62:225–8.
    1. Varadhan KK, Neal KR, Dejong CH, Fearon KC, Ljungqvist O, Lobo DN. The enhanced recovery after surgery (ERAS) pathway for patients undergoing major elective open colorectal surgery: A meta-analysis of randomized controlled trials. Clin Nutr. 2010;29:434–40.
    1. Xiong J, Szatmary P, Huang W, de la Iglesia-Garcia D, Nunes QM, Xia Q, et al. Enhanced recovery after surgery program in patients undergoing pancreaticoduodenectomy: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2016;95:e3497.
    1. Agarwal V, Thomas MJ, Joshi R, Chaudhari V, Bhandare M, Mitra A, et al. Improved outcomes in 394 pancreatic cancer resections: The impact of enhanced recovery pathway. J Gastrointest Surg. 2018;22:1732–42.
    1. Siddharthan R, Dewey E, Billingsley K, Gilbert E, Tsikitis VL. Feasibility and benefits of an enhanced recovery after surgery protocol for patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy: A single institution experience. Am J Surg. 2019:pii: S0002-9610(19)30599-9.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner